Three Japan Firms, AZ In Neglected Disease ‘Booster’ Plan
This article was originally published in PharmAsia News
The Drugs for Neglected Diseases initiative (DNDi) and four pharmaceutical firms are collaborating on a new project to find therapies for two of the world's most neglected diseases: leishmaniasis and Chagas disease.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.